Skip to content
Screener

Myriad Genetics MYGN Q2 2026 earnings

Reported July 30, 2026 · After market close

Revenue$190.7MMiss by $15.3M
EPS-$0.25Miss by $0.19
Revenue estimate$206.0M
EPS estimate-$0.06
“During the quarter, we advanced work on a strategic review with the intention to identify initiatives to increase growth, profitability, and liquidity. We have activated an initiative called Ascend to increase organizational efficiency, effectivity and scalability and are being supported by a leading professional services firm. We are also doing a rigorous evaluation of our product portfolio to determine the optimal allocation of capital and enhancement of shareholder value.”
Sam Raha

Next report

Nov 4, 2026 (In 2 days)
Revenue estimate$191.3M
EPS estimate-$0.17

Financials

Q2 2026

Income statement

See full
Revenue$190.7M-10.5%
Gross profit$127.0M-16.3%
Operating income-$38.9M+88.2%
Net income-$43.2M+86.9%
EPS (diluted)-$0.46+87.1%

Balance sheet

See full
Cash & equivalents$115.2M+37.6%
Total debt$210.5M+36.2%
Total equity$303.9M-21.7%
Total assets$638.9M-5.7%

Cash flow

See full
Operating cash flow-$8.3M+39.0%

Valuation & ratios

Valuation

as of 10/30/26
See full
Market cap$637.98M-13.8%
Enterprise value$733.28M-8.0%
P/S0.8×-0.1×

Profitability

See full
Gross margin68.8%-1.6pp
Operating margin-12.2%-5.3pp
Net margin-14%-5.8pp

Returns & leverage

See full
Return on equity-32.5%-11.3pp
Debt / equity0.7×+0.3×
Current ratio2.2×+0.8×

Segments

By product

See full
Cancer Care Continuum$114.1M—
Prenatal Health$39.8M—
Mental Health$36.8M—

FAQ

When did Myriad Genetics report Q2 2026 earnings?
Myriad Genetics (MYGN) reported Q2 2026 earnings on July 30, 2026 after market close.
What were Myriad Genetics's Q2 2026 revenue and EPS?
Myriad Genetics reported revenue of $190.7M and eps of $-0.25 for Q2 2026.
Did Myriad Genetics beat estimates in Q2 2026?
Revenue missed the consensus estimate of $206.0M by $15.3M. EPS missed the consensus estimate of $-0.06 by $0.19.
How did Myriad Genetics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 10.5% from $213.1M a year earlier.
Where can I find Myriad Genetics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0000899923-26-000070) and the 10-Q periodic report (0000899923-26-000072) directly on SEC EDGAR. The filing index links above go to sec.gov.